Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix H. LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 80.00p 79.00p 81.00p 80.50p 80.00p 80.50p 168,941 08:08:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.2 1.7 2.4 32.9 68.35

OptiBiotix Health PLC Distribution agreement for LPLDL® in Japan

11/02/2019 7:00am

UK Regulatory (RNS & others)

Optibiotix H. (LSE:OPTI)
Historical Stock Chart

2 Months : From Jan 2019 to Mar 2019

Click Here for more Optibiotix H. Charts.


RNS Number : 5500P

OptiBiotix Health PLC

11 February 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Distribution agreement for Lactobacillus plantarum LP(LDL) (R) in Japan

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has appointed EIWA Trading Co. Ltd. ("EIWA") as its exclusive distributor for LP(LDL) (R) in Japan.

The agreement grants EIWA the exclusive rights to import, market and distribute OptiBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LP(LDL) (R) in Japan for a period of three years. Market exclusivity is linked to increasing minimum annual volumes in order to maximise the financial return for both parties providing some surety of income for OptiBiotix over the next three years.

Based in Japan, EIWA was founded in 1963 as a distributor of food ingredients and flavours. It started its operations in functional ingredients 25 years ago and has been a major player in probiotics distribution in the country for the last ten years, servicing both food, dairy and food supplements companies. This agreement creates opportunities for EIWA to market LP(LDL) (R) for use as a food and dairy ingredient as well as a food supplement.

Asia-Pacific is currently the main market for probiotics (Euromonitor, 2018), and Japan accounts for 45% of it. In Japan, dairy probiotic applications are culturally very well established and their market is forecasted to grow with a sizeable CAGR of 14% until 2023. Probiotic food supplements have been gaining significant momentum over the last number of years and their market growth rates are expected to outpace those of dairy probiotic products in the abovementioned period (Research and Markets, 2018).

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this distribution agreement with EIWA. This deal provides OptiBiotix market access in Japan, the main national market for probiotics within the largest region for probiotics in the world. We have chosen EIWA as they are a well-known and respected provider of probiotics to the Japanese food, dairy and supplement industries, creating the potential to extend the use of LP(LDL) (R) beyond supplements in a major international market. This agreement is another step in OptiBiotix's strategy of building revenues and market presence of LP(LDL) (R) as the 'Intel' inside a wide range of food, dairy and supplement products around the world. We believe working with EIWA and similar partners around the world will provide the best opportunity of rapidly building LP(LDL) (R) into a valuable global brand."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 OptiBiotix Health plc                                    
 Stephen O'Hara, Chief Executive                                 Contact via Walbrook 
 Cairn Financial Advisers LLP (NOMAD) 
 Liam Murray / Jo Turner                                           Tel: 020 7213 0880 
   finnCap (Broker) 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance)                                              Tel: 020 7220 0500 
  Camille Gochez (Corporate Broking) 
   Walbrook PR Ltd                    Tel: 020 7933 8780 or 
 Anna Dunphy                                                       Mob: 07876 741 001 

About OptiBiotix -

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

February 11, 2019 02:00 ET (07:00 GMT)

1 Year Optibiotix H. Chart

1 Year Optibiotix H. Chart

1 Month Optibiotix H. Chart

1 Month Optibiotix H. Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190324 23:56:30